semaglutide compounding news november 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide" Drugmakers and pharmacists battle over

The Apex Skin Total Body Program is designed to help you lose weight safely and sustainably, guided by an expert

Medical weight loss intervention has been skyrocketing in recent years with many drugs on the market or in clinical trials, including incretin memetics or incretin receptor agonists such as Ozempic (semaglutide, SEMA) targeting glucagon-like peptide-1 (GLP-1) receptor (GLP1R) or dual agonist Mounjaro (tirzepatide) targeting GLP1R and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR)

The MHRA's Yellow Card scheme (yellowcard.mhra.gov.uk) allows patients and healthcare professionals to report suspected side effects, helping to build a comprehensive safety profile for these medications

SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways

A review*

This distinction is important for healthcare providers and patients